Table 4.

Abnormal expression of miRNA-mediated MDR related to PI3K/AKT pathway in lung cancer.

MiRNA	Expression	Target	Resistant drug	Ref.
miR-139-5p	↓	P-AKT	cisplatin	(65)
miR-29c	↓	AKT2	cisplatin	(71)
miR-20a	↓	PI3K	cisplatin	(69)
miR-25-3p	↑	PTEN	cisplatin	(42)
miR-199a-5p	↑	P62	paclitaxel	(36)
miR-107	↓	P-AKT	Paclitaxel	(72)
miR-126	↓	PI3KR2	Adriamycin,vincristine	(47)
miR-17-5p	↓	RRM2	gemcitabin	(45)
miR-34a	↓	PTEN	gefitinib	(49)
miR-522-3p	↑	P-AKT	gefitinib	(37)
miR-30a-5p	↓	P-AKT	gefitinib	(73)
miR-200c	↓	P-AKT	gefitinib	(74)
miR-223	↓	P-AKT	erlotinib	(75)
miR-135a	↑	RAC1	gefitinib	(38)
let-7c	↓	RAS	gefitinib	(76)
miR-23a	↑	PTEN	erlotinib	(39)

↑, Up-regulated expression in lung cancer; ↓,Down-regulated in lung cancer.